

Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Disease



journal homepage: www.elsevier.com/locate/apjtd

Document heading doi:10.1016/S2222-1808(14)60332-7

© 2014 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

Clinical human brucellosis in Malaysia: a case report

Tyagita Hartady¹, Mohd Zamri Saad^{1*}, Siti Khairani Bejo², Mohd Shahrom Salisi³

¹Research Centre for Ruminant Diseases, Faculty of Veterinary Medicine, Universiti Putra Malaysia 43400, Serdang, Selangor, Malaysia

²Department of Veterinary Pathology & Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia 43400, Serdang, Selangor, Malaysia

³Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia 43400, Serdang, Selangor, Malaysia

PEER REVIEW

Peer reviewer

Roberto Sousa Dias, MSc, Laboratory of Immunovirology, Department of General Biology, Federal University of Viçosa, Brazil. Tel: 55 31 8878–4339 Fax: 55 31 3899–2549 E-mail: rosousa318@yahoo.com.br

Comments

This is an interesting work, where the authors report on human infection by *B. melitensis* which is helpful for clinical diaganosis and treatment. Details on Page 152

ABSTRACT

Clinical human brucellosis is quite rare in Malaysia although seroconverters are relatively more. This report describes a case of clinical human brucellosis in Malaysia. This case involved a 29-year-old research assistant in a veterinary microbiology laboratory. She complained of intermittent fever, anorexia, profuse sweating, malaise, headache, normotensive (110/60 mm Hg), muscle pain, and arthralgia for 3 d. Blood tests against dengue and malaria were negative thus she was prescribed vitamin C, paracetamol and cough syrup for common flu. The complaints, however, persisted on and off for the next 1 month. She eventually developed anemia and hypotension (90/50 mm Hg) and started to show reduced body weight. Abdominal palpations revealed hepatomegaly and splenomegaly with pain. Thus, brucellosis was suspected before the Rose-Bengal plate test was performed, which revealed the presence of high level of antibody against *Brucella*. The same test was repeated after 14 d and the results confirmed the presence of high antibody level against *Brucella*. Following serum agglutination test, a diagnosis of brucellosis was made and she was eventually prescribed rifampicine *p.o.* once a day combined with doxycycline *p.o.* twice a day for 6 consecutive weeks before she made a full recovery.

KEYWORDS Brucellosis, Human, Malaysia

1. Introduction

Brucellosis is a multisystem disease with a broad spectrum of non-specific symptoms that generally occur within 2 weeks but sometimes up to 3 months after inoculation. In human, it developed as a result of consuming unpasteurized, contaminated goat's milk or soft cheese that had been infected with *Brucella melitensis* (*B. melitensis*)^[1]. This Gram-negative, aerobic non spore forming coccobacillus is a free-living, soil-dwelling organism that usually infects goats and sheep. In infected hosts, the bacterium appears as intracellular localization, particularly within the reticuloendothelial system^[2]. There are six species of *Brucella* and four of which are known to infect humans. They are *B. melitensis, Brucella abortus* (*B. abortus*), *Brucella suis* (*B. suis*) and *Brucella canis* (*B. canis*). *B. abortus* is found principally in cattle, *B. melitensis* in goats and sheep, *B. suis* in swine and *B. canis* in kennel–raised dogs^[3].

Both human and animal brucellosis are still endemic in some parts of the world such as Pakistan^[4], India^[5], China^[6] and Sri Lanka^[7]. About 500 000 new brucellosis cases were reported annually from all over the world^[8]. In Malaysia, *Brucella* among animals was first isolated in

^{*}Corresponding author: Mohd Zamri Saad, Research Centre for Ruminant Diseases, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 Serdang, Malaysia. Tel: +603 86093453

Fax: +6023 89471971

E-mail: mzamri@upm.edu.my

E-mail: mzamri@upm.edu

Foundation Project: Supported by a Fundamental Research Grant Scheme [07-03-11-1026FR] of the Ministry of Higher Education, Malaysia.

Article history: Received 28 Jan 2014

Received in revised form 3 Feb, 2nd revised form 15 Feb, 3rd revised form 23 Feb 2014 Accepted 13 Mar 2014 Available online 28 Apr 2014

1950 and the government embarked upon an eradication program for brucellosis (National Surveillance Program for Animal Brucellosis) in cattle, buffaloes, goats and sheep since 1978^[9]. Brucellosis in human was first reported in 2010 involving a seven–year boy after consumed a raw milk of an infected goat. Nevertheless, studies have shown seropositive humans in Malaysia, mainly among veterinarians and farmers associated with occupational exposure to animals. The seroprevalent was mainly males (90%) within the age range between 20 and 45 years old^[10]. This paper reports a case of human brucellosis involving a laboratory assistant in Malaysia.

2. Case report

A 29-year-old woman who worked as a research assistant in a veterinary microbiology laboratory complained of intermittent fever, anorexia, profuse sweating, malaise,

Table 1

The haemogram results of the patient during Brucella infection

headache, normotensive (110/60 mm Hg) and muscle pain especially of the neck and shoulder, and arthralgia for 3 d. She was one of the 9 laboratory workers who were involved in a research on isolation of *B. melitensis* from goats for the past 3 months. The next day, she was admitted to a clinic for blood tests against dengue and malaria but was found negative. Therefore, a common flu was suspected and she was prescribed vitamin C, paracetamol and cough syrup.

The complaints, however, persisted on and off for the next one month and the conditions were getting worse. Anemia and hypotension (90/50 mm Hg) were eventually developed and she started to show reduced body weight from 50 kg to 43 kg. Abdominal palpations revealed hepatomegaly and splenomegaly with pain. The hemoglobin, hematocrit and neutrophil were low while the lymphocytes and erythrocyte sedimentation rate were high during the first month of infection. Following treatment (Tables 1 and 2), the conditions improved slightly.

The nucleofidin results of the patient during <i>Diracebra</i> meetion.																
Date	RBC	Hb	PCV	MCV	MCHC	WBC	B. NEUT	S. NEUT	LYMP	MONO	EOS	BAS	THROM	PP	П	ESR
	CMM×10 ³	g/L	L/L	fL	%	CMM×10 ³	%	%	%	%	%	$\times 10^{12}/L$	$\times 10^{12}/L$	g/L	Unit	MM/HR
21-01-2013	-	12.7	40.2	-	-	5.51	-	58	32	8.0	1.0	1	184	-	-	-
29-01-2013	3.93	10.9	33.6	85.4	32.6	4.88	-	51	37	10.0	1.0	1	222	-	-	64
01-02-2013	4.04	11.4	35.0	87.0	32.6	4.63	0.14	22	18	3.7	1.0	0	260	90	2	-
04-02-2013	-	11.2	34.4	-	-	3.80	-	-	-	-	-	-	310	-	-	-
03-04-2013	3.98	11.2	34.0	85.0	32.9	4.18	0.04	23	14	2.1	1.0	0	189	74	2	-
16-04-2013	4.42	12.5	37.8	85.5	33.0	4.79	-	50	39	7.0	3.0	1	252	-	-	34
02-01-2013	4.41	12.3	38.1	-	-	4.62	_	42	47	-	-	-	232	-	-	-

RBC: Red blood cell count, Hb: Haemoglobin B, PCV: Packed-cell volume, MCV: Mean corpuscular volume, MCHC: Mean corpuscular hemoglobin concentration, WBC: White blood cell count, NEUT: Neutrophil, LYMP: Absolute lymphocyte count, MONO: Monocytes, EOS: Eosinophil, BAS: Basophils, THROM: Thrombocytes, ESR: Erythrocyte sedimentation rate.

Table 2

The blood biochemistry results of the patient during Brucella infection.

Data	TP	AST	ALT	Urea	Creatinine	Tbil	Albumin	Sodium	Potassium	Chloride
Date	g/L	U/L	U/L	mmol/L	umol/L	umol/L	g/L	mmol/L	mmol/L	mmol/L
29-01-2013	62.9	33.0	26.0	2.43	76	8.0	38.2	133.0	3.5	102.0
03-04-2013	66.5	17.9	9.9	4.30	79	3.8	42.4	138.6	5.0	103.4
16-04-2013	_	21.0	14.0	3.53	65	-	-	-	-	-

TP: Total protein, AST: Aspartate transaminase, ALT: Alanine aminotransferase, Tbil: Total bilirubin.

At this moment, either brucellosis or leptospirosis was suspected based on the symptoms and history of her previous handlings of both organisms. Therefore, the Rose– Bengal plate test (RBPT)^[11] was performed using antigen of *B. melitensis*, which revealed the presence of high level of antibody. The same test was repeated after 14 d and the results confirmed the presence of high antibody level against *B. melitensis* (Table 3). Eventually, standard agglutination test was performed^[12], which revealed the presence of high level of antibody titer against *Brucella* (1:40). The same tests were repeated after 14 d and the results confirmed the presence of high antibody level against *Brucella* (Table 3).

Based on the serological tests and PCR, a diagnosis of brucellosis was made. She was eventually prescribed rifampicine *p.o.* once a day combined with doxycycline *p.o.* twice a day for 6 consecutive weeks.

Table 3

Results of Rose Bengal plate test (RBPT) prior to, during and post-treatment periods.

Date	Results	Description
31 January 2013 (Pre-treatment)	+++	Agglutination<3 seconds
4 April 2013 (During treatment)	++	Agglutination<15 seconds
16 June 2013 (Post-treatment)	+	Agglutination<30 seconds

3. Discussion

Brucellosis, particularly those caused by *B. melitensis* is among the most frequently reported laboratory–acquired infections. About 30% to 100% of cases of brucellosis in humans were obtained from laboratory exposures^[13]. In this case, the patient was a microbiology laboratory worker, thus highly at risk of getting brucellosis through unpredicted exposure to cultures from clinical specimens. Transmission was believed to occur mainly via inhalation^[14]. Nevertheless, human brucellosis appears to be quite rare in Malaysia, making the suspicion level among clinicians to be quite low.

RBPT has been proven as a cheap, rapid and effective serologic test compared to other serological tests, such as serum agglutination test, coomb test, compliment fixation test, indirect immunofluorescent antibody test and enzyme–linked immunosorbent assay (ELISA). With the minimum of equipment, RBPT can be performed and the results can be read by the naked eye. However, the specificity and sensitivity are unclear but the results are reliable^[15]. In our study, serum agglutination test was also performed as second serology test to support the diagnosis. serum agglutination test had been recognised as the most commonly used test that is able to detect antibodies against *B. abortus, B. suis* and *B. melitensis* but not *B. canis*^[12,16].

This patient showed many of the acute symptoms of human brucellosis, which included undulating fever, myalgia and other clinical manifestations such as splenomegaly, hepatomegaly and spondylitis^[17]. Infective endocarditis, although rare, is the most devastating complication from systemic brucellosis and could require surgical intervention. Splenic, hepatic and pulmonary abscesses can also develop. Lymphadenopathy is found in 10% to 20% of cases and splenomegaly or hepatomegaly in 20% to 30% of cases^[18]. Other rare conditions include deep vein thrombosis, eukocytoclastic vasculitis, meningitis and nephritis. Ocular manifestations include optic neuritis, papilledema and uveitis^[19]. Common hematologic findings include leukopenia, anemia, and thrombocytopenia^[20].

The standard treatment for human brucellosis is doxycycline 100 mg *p.o.* twice a day and rifampcine 450 mg/ day *p.o.* for 6 weeks^[21]. However, the standard treatments vary depending on the patient's age and pregnancy status^[22]. There was no statistical difference regarding the type of combination therapy on the early clinical response of human brucellosis. Nevertheless, the recommended treatments are as follows. For children younger than 8 years, a combination therapy of trimethoprim–sulfamethoxazole and aminoglycoside^[23] or a combination of rifampicin and trimethoprim–sulfamethoxazole for 45 d is needed^[24]. For those aged 8 years and older, a combination of doxycycline and rifampin or a rifampicin and gentamicin combination could be prescribed^[25]. Rifampicin combined with ciprofloxacin for 30 d has also been shown to be effective and offers the advantage of a shorter-treatment duration^[26].

Guideline from the Center of Disease Control and Prevention (CDC) on management of laboratory exposures to *Brucella* spp. advises serological follow-up and antibiotic prophylaxis. The rationale for serological follow-up is to identify and treat asymptomatic infected patients, although the benefit is not proven. In one exposure incident, treating seroconverted asymptomatic workers led to milder symptoms compared with those treated for clinically apparent disease^[18]. Prolonged follow-up of exposed workers is required, since the incubation period varies from 1 week to 5 months. Similarly, the benefit of early prophylaxis to the highest risk group was not confirmed since no seroconversion was produced in the high-risk staffs tested^[27].

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

This study is financially supported by a Fundamental Research Grant Scheme [07–03–11–1026FR] of the Ministry of Higher Education, Malaysia.

Comments

Background

Brucella infections are rare in humans, despite being present in many animals used for consumption. The infection cases reported in humans is essential so that we can discuss investment in the management of infected animals, research laboratories safety and public health.

Research frontiers

This paper is a case report of human infection by *B*. *melitensis*, which is already known to be capable of infecting humans.

Related reports

In this work the authors use Rose–Bengal plate test (RBPT) to finalize the diagnosis of brucellosis. After reviewing the clinical and symptomatic aspects, the diagnosis is finalized by the intersection of clinical data with the Rose–Bengal plate test.

Innovations & breakthroughs

Brucellosis is a major zoonosis and in this work the authors demonstrated the use of rapid tests to screen for possible infections. The addition of clinical information with serological data acquired by the Rose–Bengal plate test confirms the *Brucella* infection in humans.

Applications

The use of serological tests, as Rose–Bengal plate test, to screen positive cases of *Brucella* makes the procedure faster and cheaper, allowing greater agility in identifying and initiating treatment.

Peer review

This is an interesting work, where the authors report on human infection by *B. melitensis* which is helpful for clinical diaganosis and treatment.

References

- [1] Ramin B, MacPherson P. Human brucellosis. BMJ 2013; 341: c4545.
- [2] Shaqinah N, Mazlina M, Zamri-Saad M, Hazilawati H, Jasni S. *In vitro* penetration and survival of *Brucella melitensis* in lymphocytic cells of goats. *Online J Vet Res* 2012: **16**(3): 104–110.
- [3] Kang SI, Her M, Kim JW, Kim JY, Ko KY, Ha YM, et al. Advanced multiplex PCR assay for differentiation of *Brucella* species. *Appl Environ Microbial* 2011: 77(18): 6726–6728.
- [4] Akhtar R, Chaudhry PZI, Shakoori PAR, Ahmad MUD, Aslam A. Comparative efficacy of conventional diagnostic methods and evaluation of polymerase chain reaction for the diagnosis of bovine brucellosis. *Vet World* 2010; **3**: 53–56.
- [5] Ghodasara SN, Roy A, Bhanderi BB. Comparison of Rose Bengal Plate Agglutination, Standard tube agglutination and Indirect ELISA tests for detection of *Brucella* antibodies in cows and buffaloes. *Vet World* 2010; **3**: 61–64.
- [6] Zhang Z, Yu S, Wang X, Dong S, Xu J, Wang J, et al. Human brucellosis in the People's Republic of China during 2005–2010. Int J Infect Dis 2013; 17(5): e289–e292.
- [7] Priyantha MAR. Identification of biovars of *Brucella abortus* in aborted cattle and buffaloes herd in Sri Lanka. *Vet World* 2011; 4: 542–545.
- [8] Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: A systematic review of disease frequency. *PLoS Negl Trop Dis* 2012; 6(10): e1865.
- [9] Bamaiyi PH, Abd-Razak NS, Zainal MA. Seroprevalence and economic impact of eradicating zoonotic brucellosis in Malaysia: A case study of Melaka state of Malaysia. *Vet World* 2012; 5(7): 398– 404.
- [10] Jama'ayah MZ, Heu JY, Norazah A. Seroprevalance of brucellosis among suspected cases in Malaysia. *Malaysian J Pathol* 2011; 33(1): 31–34.
- [11] Swai ES, Schoonman L. The use of Rese Bengal plate test to assess cattle exposure to *Brucella* infection in traditional and smallholder dairy production system of Tanga Region of Tanzania. *Vet Med Int* 2010; doi: 10.4061/2010/837950.

- [12] Lousiana Office of Public Health. Infectious disease epidemiology program. Louisiana: Louisiana Department of Health and Hospitals.[Online] Available from: www.infectiousdisease.dhh.louisiana.gov.[Accessed on 21 September 2013]
- [13] Traxler RM, Lehman MN, Bosserman EA, Guerra MA, Smith TL. A literature review of laboratory–acquired brucellosis. J Clin Microbiol 2013; 51(9): 3055–3062.
- [14] Sophie R, Michael L, Marcel B, Earl R. Prevention of laboratory acquired brucellosis. *Clin Infect Dis* 2004; 38: e119–e122.
- [15] Shahaza O, Khairani-Bejo S, Zunita Z, Bahaman AR. In-house Rose Bengal Plate Agglutination Test (RBPT) for a rapid diagnosis of brucellosis in goats in Malaysia. *Int J Trop Med* 2009; 4(3): 116– 118.
- [16] WHO. Brucellosis in humans and animals: WHO guidance. Geneva: World Health Organization; 2005.
- [17] Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: A systematic review and meta–analysis. *PLoS Negl Trop Dis* 2012; 6(12): e1929.
- [18] Corbel MJ. Brucellosis in humans and animals. Geneva: World Health Organization; 2006. [Online] Available at: http://www.who. int/csr/resources/publications/Brucellosis.pdf. [Accessed on 3 June 2013]
- [19] Rolando I, Olarte L, Vilchez G, Lluncor M, Otero L, Paris M, et al. Ocular manifestations associated with brucellosis: a 26-year experience in Peru. *Clin Infect Dis* 2008; 46(9): 1338-1345.
- [20] Sari I, Altuntas F, Hacioglu S, Kocyigit I, Sevinc A, Sacar S, et al. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis. *Am J Hematol* 2008; 83: 334–339.
- [21] Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systemic review and metaanalysis of randomised controlled trials. *BMJ* 2008; **336**: 701–708.
- [22] Figueroa Damian R, Rojas Rodriguez L, Marcano Tochon ES. [Brucellosis in pregnancy: course and perinatal results]. *Ginecol Obstet Mex* 1995; 63: 190–195. Spanish.
- [23] Lubani MM, Dudin KI, Sharda DC. A multicenter therapeutic study of 1100 children with brucellosis. *Pediatr Infect Dis J* 1989; 8: 75– 78.
- [24] Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. *Drugs* 1997; 53: 245–256.
- [25] Joint FAO/WHO Expert Committee on Brucellosis, WHO. FAO/WHO Expert Committee on brucellosis: sixth report; 1985 Nov 12–19 November 1985; Geneva, Switzerland. Geneva: World Health Organization; 1986.
- [26] Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. *Eur J Clin Microbiol Infect Dis* 1999; 18: 535–538.
- [27] Mendoza-Núñez M, Mulder M, Franco MP, Maas KS, Castañeda ML, Bonifacio N, et al. Brucellosis in household members of *Brucella* patients residing in a large urban setting in Peru. Am J Trop Med Hyg 2008; 78: 595-598.